3 completed, 3 terminated. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Terminated 3 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow fosaprepitant: new trials by email Literature Review of fosaprepitant trials Research Report on fosaprepitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma fosaprepitant - Nasopharyngeal Carcinoma | Phase 1 | Completed | Sun Yat-sen University | 100 | 2020-11-24 | 2022-11-07 |
| Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Selinexor, Melphalan, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 22 | 2017-07-20 | 2022-11-04 |
| Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy granisetron transdermal system, fosaprepitant dimeglumine, laboratory biomarker analysis - Breast Cancer, Nausea | Phase 1 | Terminated | University of Southern California | 29 | 2012-09-04 | 2017-11-17 |
| Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183) Fosaprepitant 150 mg, Aprepitant 165 mg, Aprepitant 250 mg - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 1 | Completed | Merck Sharp & Dohme LLC | 16 | 2010-04-01 | 2015-02-25 |
| A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134) Experimental: aprepitant, Experimental: fosaprepitant, Comparator: ondansetron - Chemotherapy-Induced Nausea and Vomiting | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 92 | 2009-02-05 | 2018-09-25 |
| Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy fosaprepitant dimeglumine, systemic chemotherapy, survey administration - Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Terminated | OHSU Knight Cancer Institute | 34 | 2008-08-01 | 2017-05-09 |
Vomiting (4) · Nausea (2) · Breast Neoplasms (1) · Multiple Myeloma (1) · Nasopharyngeal Carcinoma (1)
Merck Sharp & Dohme LLC (2) · H. Lee Moffitt Cancer Center and Research Institute (1) · OHSU Knight Cancer Institute (1) · Sun Yat-sen University (1) · University of Southern California (1)
United States (3) · China (1)
Agustin Garcia (1) · Joseph Bubalo, PharmD, BCPS, BCOP (1) · Ming-Yuan Chen, MD,PhD (1) · Taiga Nishihori, M.D. (1)
PMID 22739139, PMID 25770814, PMID 33023948, PMID 37498596
P30CA069533 (1)